Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07062588 · ClinicalTrials.gov registry record · Phase 2
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
A Phase 2 study of Osteogenesis Imperfecta (OI), sponsored by Angitia Incorporated Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT07062588 is a Phase 2 study of Osteogenesis Imperfecta (OI) that is actively recruiting participants, run by Angitia Incorporated Limited. The registered enrollment target is 80 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT07062588, a Phase 2 study of Osteogenesis Imperfecta (OI), is actively recruiting participants, sponsored by Angitia Incorporated Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AGA2115
Study Locations (20)
Other
- Instituto de Investigaciones Metabolicas Dr. Zanchetta - Sede Centro - Buenos Aires
- Monash University-Monash Medical Centre (MMC) - Melbourne
- Royal Melbourne Hospital - Parkville
- Royal North Shore Hospital (RNSH) - Saint Leonards
- Adults Westmead Hospital - Westmead
- Aarhus Universitetshospital - Medicinsk Endokrinologisk Afdeling (MEA) Ambulatoriet - Tage-Hansens Gade - Aarhus
- Odense Universitetshospital - Odense
- Hopital Edouard Herriot - Lyon
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Lariboisiere - Paris
Arizona
- Phoenix Children's - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- Nemours/Alfred I. duPont Hospital for Children - Wilmington
Indiana
- Indiana University School of Medicine, Department of Medicine and Pediatrics Division of Endocrinology - Indianapolis
Missouri
- Washington University School of Medicine in St. Louis - St Louis
Nebraska
- University of Nebraska Medical Center (UNMC) - Diabetes and Endocrinology Center - Omaha
New Mexico
- New Mexico Clinical Research & Osteoporosis Center, Inc. (NMCROC) - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07062588
The ClinicalTrials.gov registry entry for NCT07062588 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angitia Incorporated Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteogenesis Imperfecta (OI) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07062588 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07062588 about?
NCT07062588 is a clinical study titled "Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)". This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
What is the current status of trial NCT07062588?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-12. Estimated completion is 2029-02.
What conditions does trial NCT07062588 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta (OI).
What interventions are being tested in trial NCT07062588?
The interventions under investigation include: Placebo (OTHER), AGA2115 (DRUG).
Who is sponsoring clinical trial NCT07062588?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07062588 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Delaware, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.